SHOREPOWER TECHNOLOGIES INC. 8-K

What Happened Shorepower Technologies, Inc. (filed 8-K Feb 23, 2026) announced that on February 17, 2026 it entered into a Merger Agreement to merge with Aeternum Health LLC, with Shorepower as the surviving entity. As part of the deal, Jeff Kim will resign as President, CEO and sole director, and Paul Mann (Manager of Aeternum Health) will become President, CEO and the sole board member. Shorepower will spin out its current transportation-electrification assets and refocus on developing longevity/health products and services tied to a novel peptide mix. The company also plans a name change to Aeternum Health Inc., will seek a new trading symbol, and will increase authorized common shares from 100 million to 250 million.

Key Details

• Merger date: Agreement signed Feb 17, 2026; closing subject to customary conditions, including Aeternum providing audited financials since its Oct 2025 inception.
• Ownership and securities: Paul Mann will receive shares representing 51% of Shorepower’s issued and outstanding common stock at closing plus 2,000,000 shares of Series B preferred stock (each Series B share carries voting power equal to 40 common shares).
• Aeternum assets to be transferred: know‑how and data from a single patient related to a novel peptide mix (and resulting IP), a minimum of $1.5 million in cash, and a business for commercializing the peptide mix.
• Jeff Kim share cancellations: Kim agreed to cancel 8,287,500 existing common shares at closing and, after two planned healthcare mergers arranged by Aeternum, to cancel an additional 2,275,000 shares, then another 2,527,258 shares at a third closing — totaling 13,000,000 shares cancelled.

Why It Matters This filing signals a change of control and a major strategic pivot: Shorepower will effectively become a healthcare/longevity company under new leadership and capital structure. Investors should note the transfer of control (Paul Mann ~51% ownership plus high‑voting preferred stock), the planned name and business change, the increased authorized share count, and the reliance on Aeternum’s assets (including $1.5M cash and patient data/IP). The merger closing is conditional (not final) pending customary requirements such as audited financials from Aeternum, so timing and final terms could change.